Cymbalta Adds Musculoskeletal Pain Claim Despite Advisory Committee Concerns
This article was originally published in The Pink Sheet Daily
Executive Summary
Label for duloxetine's new use emphasizes that efficacy was shown only in patients with chronic lower back pain and osteoarthritis.
You may also be interested in...
Patient Selection For Analgesic Trials To Be Improved Under Public-Private ACTION Initiative
A new collaborative project between FDA and the University of Rochester could help drugmakers salvage pain drugs that have garnered negative clinical trial results but may have efficacy in a narrower population by creating more sensitive assays.
Patient Selection For Analgesic Trials To Be Improved Under Public-Private ACTION Initiative
A new collaborative project between FDA and the University of Rochester could help drugmakers salvage pain drugs that have garnered negative clinical trial results but may have efficacy in a narrower population by creating more sensitive assays.
Chronic Pain Indications Will Be Harder To Come By, FDA Says
A general chronic pain indication may elude Eli Lilly's Cymbalta near the finish line because FDA has changed its thinking about the evidence needed to support the claim